

# Explaining natural product-drug interactions with biomedical knowledge graphs

Sanya Bathla Taneja

PhD student, Intelligent Systems Program

[sbt12@pitt.edu](mailto:sbt12@pitt.edu)

April 16, 2021

# Natural Products Promoted for Complementary Health



Complementary  
Health Approaches –  
herbal/dietary  
supplements



# Natural Products Promoted for Complementary Health

## Complementary Health Approaches – Pain Relief

### Benefits of Kratom



Kratom – promoted for analgesic/pain relief

### 10 Health Benefits of Marijuana



Cannabis/cannabidiol (CBD)– promoted for all kinds of health benefits

# Natural Product (NP) Safety Concerns



St. John's wort

+ cyclosporin → Transplant or graft rejection

- NPs are not nearly as regulated as drugs by the FDA
- Large number of NPs now available
  - 76,000 in dietary supplements database
- Increasing consumer market for NPs
  - Up to 18% adults in US

# NP Safety Concerns

## Adverse events due to intake of NP

- Concomitant intake of drugs and NPs by older adults
  - Up to 80% adults in US
- Generally, natural products not reported to physicians or in EHR
- Effects range from mild, severe to deadly depending on the interaction
- Occurs when substance/constituent interacts with a drug or inhibits it
  - Makes drug ineffective and/or toxic to body

# NP Safety Concerns

## FDA Adverse Event Reporting System (FAERS)

- Platform for consumers, physicians, legal agencies to report drug interactions and adverse effects
- Able to find natural products in reports

### ***New Examples – natural products with > 20 reports in FAERS since 2004***

Natural Product	Reported Adverse Events
Kratom	Vomiting, pulmonary congestion, death
Horse Chestnut	Somnolence, gastroesophageal reflux disease, coma
Cannabis	Cardiac arrest, respiratory issues
Green Tea	Rash, burning skin sensation, itchy skin, erythema
Cinnamon	Increased blood glucose, abdominal pain
Saw Palmetto	Death

# NP Safety Concerns Related to Interaction with Drugs

## Examples

Widely studied  
and known

Grapefruit juice

One whole grapefruit or  
small glass of juice –  
common food item

Interacts with

Antiarrhythmic agents, antihistamines, statins,  
benzodiazepines, cough suppressant etc.

St. John's wort

Treat mild to moderate  
depression, menopause  
symptoms

Interacts with

HIV protease inhibitors, cyclosporin, hormonal  
contraceptives, antineoplastic agents, Xanax,  
antidepressants, barbiturates, immunosuppressive  
drugs, cough suppressant etc.

# NP Safety Concerns Related to Interaction with Drugs

## Examples

Widely studied  
and known

### Grapefruit juice


One whole grapefruit or  
small glass of juice –  
common food item

Antiarrhythmic  
agents,  
antihistamines,  
statins,  
benzodiazepines,  
cough  
suppressant etc.


### Adverse Events

- Rhabdomyolysis
- Torsade de pointes
- Respiratory depression
- Nephrotoxicity
- Gastrointestinal bleeding
- Bone marrow suppression


# Pharmacokinetic Drug Interactions



# Pharmacokinetic NP-Drug Interactions



# Pharmacokinetic NP-Drug Interactions




# Pharmacokinetic NP-Drug Interactions



St. John's wort

Treat mild to moderate depression, menopause symptoms

affects





CYP3A4,  
P-glycoprotein

Major metabolizing enzyme, drug transporter

drug B


E.g. hormonal contraceptive

metabolizes



# Discovering Pharmacokinetic NP-Drug Interactions

Understanding the mechanism is key to preventing major adverse events due to pharmacokinetic interactions.



# Discovering Pharmacokinetic NP-Drug Interactions

In vitro screening

In vitro-in vivo  
extrapolation (IVIVE)

Clinical studies


Kratom

Green tea

Goldenseal

Licorice

Cinnamon  
(in progress)



2015-2021,  
2021-ongoing

# Discovering Pharmacokinetic NP-Drug Interactions

In vitro screening

In vitro-in vivo extrapolation (IVIVE)

Clinical studies

Kratom

Green tea

Goldenseal

Licorice

Cinnamon  
(in progress)



2015-2021,  
2021-ongoing

*Expanding investigation to over 600 known unique natural products*

# Pharmacokinetic NP-Drug Interactions Signal Detection

***New Examples – natural products with > 20 reports in FAERS since 2004***

Natural Product	Reported Adverse Event
Kratom	Vomiting, pulmonary congestion, death
Horse Chestnut	Somnolence, gastroesophageal reflux disease, coma
Cannabis	Cardiac arrest, respiratory issues
Green Tea	Rash, burning skin sensation, itchy skin, erythema
Cinnamon	Increased blood glucose, abdominal pain
Saw Palmetto	Death

*Others include adverse effects from grapefruit juice and St. John's wort.*

# Objectives of My Research

Develop an automated hypothesis generation tool that can explain


- mechanistic information about pharmacokinetic interactions
- pathways that lead to adverse events.

**Overall goal:**

Using signals generated from FAERS and poison center reports, identify natural products with risks, generate hypotheses to explain the pharmacokinetic natural product-drug interaction and mechanism, and validate with in vitro and clinical studies.


# Biomedical Knowledge Graphs

- Graph structure with nodes and edges
  - Nodes -> entities
  - Edges -> relationships
- Heterogeneous data sources
  - Ontologies (Gene Ontology, Pathway Ontology, MONDO Disease Ontology)
  - Drug databases (Drug Bank, Drug Central)
  - Literature
- Can be existing curated knowledge or new information




# Biomedical Knowledge Graphs: Ontology

- Hierarchical representation of entities in a domain with formal relations defined between the entities.
- Examples:
  - Gene ontology
  - Disease ontology
  - Chemical Entities of Biological Interest (ChEBI) ontology




# Methods

**Goal: Use search algorithms and heuristics to find mechanistic pathways and hypotheses that explain pharmacokinetic natural product-drug interactions and adverse events.**



# Methods



# Semantic Integration of Data

Diabetes mellitus	<i>subClassOf</i>	Glucose intolerance
Glucose intolerance	<i>towards</i>	Glucose import
Glucose import	<i>MOLECULARLY_INTERACTS_WITH</i>	Progesterone
Progesterone	<i>INTERACTS_WITH</i>	MPO
MPO	<i>CAUSES_OR_CONTRIBUTES_TO_CONDITION</i>	Alzheimer disease

# Semantic Integration of Data

Human Phenotype Ontology

*subClassOf*

Human Phenotype Ontology

Diabetes mellitus

*subClassOf*

Glucose intolerance

Glucose intolerance

*towards*

Glucose import

Glucose import

*MOLECULARLY\_  
INTERACTS\_WITH*

Progesterone

Progesterone

*INTERACTS\_WITH*


MPO

MPO


*CAUSES\_OR\_  
CONTRIBUTES\_TO\_  
CONDITION*

Alzheimer disease


# Semantic Integration of Data




# Semantic Integration of Data




# Semantic Integration of Data




# Semantic Integration of Data: PheKnowLator



# Semantic Integration of Data: PheKnowLator



# Semantic Integration of Data: PheKnowLator



# Semantic Integration of Data

## Data Sources

Cell Ontology

Cell Line Ontology

Chemical Entities of Biological Interest (ChEBI) Ontology

Gene Ontology (GO)

Human Phenotype Ontology (HPO)

Mondo Disease Ontology

Pathway Ontology

Protein Ontology

Relations Ontology (RO)

Sequence Ontology

Uber-Anatomy Ontology

Drug Bank

Drug Central


Ontology of Adverse Events (OAE)

Drug-Drug Interaction Evidence Ontology (DIDEO)

Current knowledge graph version

78,317,102 triples

# Methods



# Standardization of Terminology

Why standardization?

- Standard identifiers
- Interoperability
- Access to domain relevant information (genus, species, constituents, chemical characteristics)
- Comprehensive coverage of natural products
- Non-ambiguous names

Potential standardization data sources:

- **FDA Global Substance Registration System (G-SRS)**
- Dietary Supplement Label Database (DSLD)
- Licensed Natural Health Products Database (Canada)
- Unified Medical Language System (UMLS)
- Others (NDF-RT, RxNorm, Natural Medicines Database, RxNorm, MESH, SNOMED-CT)

# Standardization of Terminology

## Global Substance Registration System (G-SRS)

### Goals of standardization with G-SRS:

- Create vocabulary of natural products to map “drugs” (user input strings) in FAERS to standard terminology
- Import natural products (and characteristics) into knowledge graph



Search

Overview	>
Names 18	>
Classification 4	>
Identifiers 10	>
Metabolites 28	>
Active Moiety 1	>
Constituents 8	>
Variant Concepts 2	>
Audit Info	>
References 42	>

## GREEN TEA LEAF

### Overview

Substance Class Structurally Diverse

Record UNII W2ZU1RY8B0

Record Protection Status Public record

Record Status Validated (UNII)

Source Materials Class ORGANISM

Source Materials Type PLANT

Source Materials Parent




CAMELLIA SINENSIS WHOLE

# Standardization of Terminology: G-SRS

*Natural products with > 20 reports in FAERS since 2004*

Natural Product	Reported Adverse Event
Kratom	Vomiting, pulmonary congestion, death
Horse Chestnut	Somnolence, gastroesophageal reflux disease, coma
Cannabis	Cardiac arrest, respiratory issues
Green Tea	Rash, burning skin sensation, itchy skin, erythema
Cinnamon	Increased blood glucose, abdominal pain
Saw Palmetto	Death


# Methods



# Knowledge Representation


ChEBI: Chemical Entities of Biological Interest

- Dictionary of molecular entities
- Identifiers, names, synonyms, chemical characteristics
- “Relations” between entities – has\_functional\_parent, has\_role, is\_enantiomer\_of
- Large number of drugs and chemicals
- Only some natural product constituents (mitragynine – kratom, catechin(s)– green tea)



# Knowledge Representation


## Semantic Representation




Source: Dr. James J. Cimino, NIH Clinical Center.

- Knowledge graph made of triples (*subject-predicate-object*)
- Goal: Extend the ChEBI ontology with natural product information from G-SRS and NaPDI Center
- Steps:
  - Build semantic representations
  - Generate ontology/web ontology language files
  - Merge into knowledge graph

# Knowledge Representation



# Methods



# Machine Reading

Challenge: Incomplete information in existing data sources

- No inhibition/interactions in other data sources (G-SRS, LNHPD, DSLD)
- Drug databases (Drug Bank, Drug Central – drug drug interaction gold standard) do not contain the NP constituents
- Research on natural products since 1900s
  - suggested hypothesis
  - animal models
  - clinical studies
  - observational reports

**Thus, we use PubMed and SCOPUS indexed articles with mechanistic information about natural products and their constituents.**

- Other sources:
  - Natural Medicines database (manually compiled from literature and systematic reviews)
  - ChEMBL (literature-based)

# Machine Reading

- PubMed and SCOPUS indexed articles with mechanistic information about natural products and their constituents
- INDRA: Integrated Network and Dynamical Reasoning Assembler
- REACH: Reading and Assembling Contextual and Holistic Mechanisms from Text
- **Hypothesis: enhancing the KG to include literature related to the natural products will improve our ability to find mechanistic explanations for pharmacokinetic NPDIs and adverse events.**
- Extract INDRA statements as subject-predicate-object triples and merge into knowledge graph
  - Subject and object grounded in OBO ontologies
  - Belief scores (probabilistic)
  - Deduplication
  - Evidence-based

# Machine Reading

Kratom results


Subject	Predicate	Object	Sentence	Belief
Mitragynine	IncreaseAmount	CYP1A2	Mitragynine was found to induce mRNA and protein expression of CYP1A2.	0.65
Mitragynine	Inhibition	Quinidine	..mitragynine exhibited low permeability across the cell monolayer but inhibited digoxin transport, similar to quinidine.	0.65
Mitragynine	Inhibition	G_protein	In addition, mitragynine was also found to inhibit the hERG1a and GIRK (G protein-coupled inward rectifier potassium) channels in other heterologous expression systems50.	0.65
Mitragynine	Inhibition	STE6 (mapped from P-glycoprotein)	Mitragynine and 7-hydroxymitragynine inhibited P-glycoprotein with EC50 values....	0.65
Mitragynine	Inhibition	Kr (incorrect mapping)	Mitragynine and its analogues at low concentrations (IC50 ranging from 0.91 to 2.47 $\mu$ M) potently inhibited IKr in hiPSC-CMs.	0.95

# Hypothesis Generation

## Goal

Develop an automated hypothesis generation tool using biomedical knowledge graph that can explain

- mechanistic information about pharmacokinetic interactions
- pathways that lead to adverse events.



# Hypothesis Generation

- NP signals generated from FAERS
- Identify nodes of interest in graph (natural products, enzymes, adverse events)
- Search algorithms
  - Simple paths between 2 nodes
  - Shortest paths
  - Bidirectional search
  - Embedded search (similarity-based)

# Hypothesis Generation

## Mitragynine (Kratom)

# Seizures

PATH 1A: long-chain fatty acid metabolic process  
valproic acid is conjugate acid of *molecularly interacts with* valproic acid  
valproate

PATH 1B: Valproate is conjugate base of valproic acid  
valproic acid interacts with TSC2  
TSC2 causes or contributes to condition Seizures

# Hypothesis Generation

Mitragynine (Kratom)

Pulmonary edema

PATH 2A:

Mitragynine  
response to drug

*molecularly interacts with*  
*molecularly interacts with*

response to drug  
diphenhydramine


PATH 2B:

diphenhydramine *molecularly interacts with*  
positive regulation of biological process  
aflatoxin B1 *interacts with* GHRH  
GHRH *causes or contributes to condition*

positive regulation of biological process  
*molecularly interacts with* aflatoxin B1  
Pulmonary edema

# Evaluation

- Gold standard: clinical and in-vitro studies
- Time splicing
- Current NPs for evaluation: kratom, goldenseal, green tea, licorice, cinnamon



# Future work and work in progress

- Include information for over 600 natural products of interest
- Signal generation from FAERS database and Pittsburgh poison center reports
- Embeddings for graph completion
- Improve machine reading for better entity recognition, full text extraction pipeline, heuristics to remove noise
- Semantic representation – automated extraction from data sources
- Knowledge graph searches heuristics and closure (transitive)
- Translation to lab/clinical once a strong NPDI is identified with potential mechanism

# Thank you!



Dr. Richard Boyce (Primary Advisor), Department of Biomedical Informatics  
Dr. Sandra Kane-Gill, School of Pharmacy

Funding: [NIH Grant U54 AT008909](#)

PI: Dr. Mary Paine (Washington State University)

# **Discussion**